An interventional study of Bridge in Brain Diseases, Vertebral Artery Thrombosis and Vertebral Artery Stenosis, sponsored by MicroPort NeuroTech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-29.
Sponsored by MicroPort NeuroTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Brain Diseases with a site in China — 18 open to participants now, 19 under way, 1 of them phase 3. Brain Diseases · China.
Among the 41 studies in Brain Diseases with a site in China, this one is the 28th largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2023, is one of 18 with no phase, reaches primary completion later than 0 of the 18 other live ones, and was the 28th registered.
502 studies on the registry are indexed under Brain Diseases; 141 are open to participants now.
Browse Brain Diseases studies →18 of the 41 studies in Brain Diseases with a site in China are open now. Recruiting first, the newest first:
The Second Hospital of Anhui Medical University · Sites in China
Ages 18+
Duan Chuanzhi · Sites in China
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Healthy volunteers
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 109 Brain Diseases studies recruiting now, 53 (49%) set no upper age limit and 22 (20%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 66 across 339 interventional studies indexed under Brain Diseases.
Median enrollment 229 across the 28 interventional studies, 600 across the 13 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under MicroPort NeuroTech Co., Ltd., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort NeuroTech Co., Ltd. is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
MicroPort Scientific Corporation has 4 studies filed under Brain Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Brain Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06633809Sir Run Run Shaw HospitalTherapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion | 2026-12-31 |
| NCT07187687Xuanwu Hospital, BeijingTrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Brain Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aprospective, multicentre, single-arm clinical trial in which approximately 36 subjects would be enrolled using the Bridge 4.5 mm and 5.0 mm stent in accordance with the inclusion and exclusion criteria in this protocol. The success rate of immediate post-procedure stent target lesion treatment was recorded for all subjects, and the incidence of in-stent restenosis (≥50% stenosis) was assessed by DSA imaging follow-up at 6 months (±30 days) post-procedure. The subjects were also followed up at 30 days (±7 days), 6 months (±30 days), and 12 months (±60 days) after stent implantation to assess safety events during the follow-up period. .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bridge
Device: Bridge
Stent implantation
Incidence of in-stent restenosis at 6 months postoperatively
Time frame: 180±30 days
Technical Success
DSA suggesting residual stenosis ≤20% after implantation
Time frame: post-implantation immediately
Any death or stroke during the follow-up associated with treatment in the target vessel supply region
Number of participants with death or stroke related to treatments for target vessel blood supply area
Time frame: 1 year after stent implantation
Any death or stroke
Number of participants with death or stroke
Time frame: 1 year after stent implantation
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jul 2024, 10 months after the start.
Of 117 interventional studies with no phase under Brain Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 54. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MicroPort NeuroTech Co., Ltd. →